Ventral Hernia Treatment Market Report 2026

The ventral hernia treatment market size has grown strongly in recent years. It will grow from $5.22 billion in 2025 to $5.59 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rising incidence of abdominal hernias, increasing surgical intervention rates, expansion of laparoscopic surgery adoption, growing availability of surgical mesh products, improved diagnostic imaging utilization.

The ventral hernia treatment market size is expected to see strong growth in the next few years. It will grow to $7.3 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to increasing adoption of robotic surgery platforms, growing demand for tension-free repair techniques, expansion of ambulatory surgical centers, rising focus on reducing hernia recurrence rates, increasing investments in advanced surgical technologies. Major trends in the forecast period include increasing adoption of robotic-assisted hernia repair, rising use of advanced hernia mesh materials, growing preference for minimally invasive procedures, expansion of day-care surgical treatments, improved post-surgical recovery protocols.

The increasing prevalence of obesity is expected to drive growth in the ventral hernia treatment market in the coming years. Obesity is a medical condition characterized by an excessive accumulation of body fat that significantly affects an individual’s health. The rise in obesity is attributed to poor diet, sedentary lifestyle, genetic predisposition, lack of physical activity, environmental factors, and emotional stress. Ventral hernia treatment aids patients with obesity by managing complications related to excess weight, alleviating strain on the abdominal wall, reducing the risk of hernia recurrence, and improving overall abdominal strength, which supports mobility and encourages healthier lifestyle choices. For instance, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately one in eight people globally were struggling with obesity. This included 2.5 billion adults aged 18 years and older who were overweight, with 890 million classified as obese. Among adults, 43% were overweight, and 16% were obese. Additionally, the number of overweight children under the age of five reached 37 million. Therefore, the increasing prevalence of obesity is driving growth in the ventral hernia treatment market.

Major companies operating in the ventral hernia treatment market are focusing on technological innovations, such as laparoscopic and open hernia mesh fixation devices, to improve surgical outcomes, minimize complications, and enhance patient recovery. Laparoscopic and open hernia mesh fixation devices are medical tools used to secure mesh during hernia repair procedures, either through minimally invasive laparoscopic methods or traditional open surgery. For instance, in March 2024, TELA Bio Inc., a US-based medical technology company, launched the LIQUIFIX FIX8 laparoscopic and LIQUIFIX precision open hernia mesh fixation devices in the U.S. LIQUIFIX FIX8 is intended for minimally invasive repairs, while LIQUIFIX precision is used for open femoral and inguinal hernia repairs. These FDA-approved devices use liquid anchors to secure mesh without penetrating tissue, reducing trauma and the risk of complications. With over 1.2 million hernia procedures performed annually in the U.S., LIQUIFIX provides precision and safety in sensitive areas while minimizing the risk of vascular or nerve injury.

In August 2023, Steris plc, an Ireland-based medical device company, acquired surgical instrumentation assets from Becton, Dickinson, and Company for an undisclosed amount. Through this acquisition, Steris plc expanded its portfolio in the surgical instrumentation market by obtaining advanced tools and technologies previously owned by Becton, Dickinson, and Company. This strengthens Steris’s ability to provide comprehensive solutions for hospitals and surgical centers, enhances its position in the medical device industry, and supports its growth in the global healthcare market. Becton, Dickinson, and Company is a US-based medical technology company that offers ventral hernia treatment solutions.

Major companies operating in the ventral hernia treatment market are Johnson & Johnson Services Inc., Medtronic Plc, Becton, Dickinson and Company (BD), Braun Melsungen AG, Olympus Corporation, W.L. Gore and Associates Inc, STERIS Plc, Cook Medical Inc, KARL STORZ, Cooper University Health Care, Mölnlycke Health Care, Integra LifeSciences Holdings, ConMed Corporation, Aesculap Inc, Richard Wolf GmbH, Ethicon Inc, Microline Surgical, Hernia Mesh S.R.L., Insightra Medical Inc, Advanced MedTech Solutions Pvt Ltd.

North America was the largest region in the ventral hernia treatment market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the ventral hernia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ventral hernia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the ventral hernia treatment market by increasing costs of imported surgical meshes, robotic surgery systems, laparoscopic instruments, and diagnostic imaging equipment. Hospitals and ambulatory surgical centers in North America and Europe are most affected due to reliance on imported surgical devices, while Asia-Pacific faces cost pressures on advanced procedure adoption. These tariffs are increasing procedure costs and capital investment requirements for healthcare providers. At the same time, they are encouraging local production of surgical meshes, regional assembly of surgical instruments, and wider adoption of cost-optimized hernia repair technologies.

The ventral hernia treatment market research report is one of a series of new reports that provides ventral hernia treatment market statistics, including ventral hernia treatment industry global market size, regional shares, competitors with a ventral hernia treatment market share, detailed ventral hernia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the ventral hernia treatment industry. This ventral hernia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ventral hernia treatment involves medical procedures and interventions aimed at repairing hernias in the abdominal wall. This typically includes robotic-assisted surgery, tension-free mesh repair, and laparoscopic intraperitoneal techniques. The goal of treatment is to reposition displaced tissues, strengthen the abdominal wall, and prevent recurrence. These procedures help relieve pain, restore normal function, and reduce the risk of complications such as bowel obstruction or strangulation.

The main types of ventral hernia treatment include epigastric (stomach area) hernia, umbilical (belly button) hernia, and incisional hernia. An epigastric hernia occurs when fatty tissue pushes through a weakened area in the upper abdominal wall, between the sternum and the belly button. Diagnosis can be made using ultrasound, computed tomography (CT) scans, and magnetic resonance imaging (MRI), and treatment options include open hernia surgery, laparoscopic surgery, and robotic hernia surgery. These treatments are used by hospitals, ambulatory surgical centers, and clinics.

The ventral hernia treatment market consists of revenues earned by entities by providing services such as surgical consultations, hernia repair surgeries, post-operative care, diagnostic imaging and others. The market value includes the value of related goods sold by the service provider or included within the service offering. The ventral hernia treatment market also includes sales of fixation devices, surgical instruments, wound care products, surgical sutures and staplers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.